MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. NTHI
9. SPY
10. EVMN

Go back to MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
MACROGENICS (NASDAQ: MGNX) Delayed: 4.08 -0.24 (5.56%)
Previous Close $4.32    52 Week High $36.11 
Open $4.29    52 Week Low $14.84 
Day High $4.30    P/E 10.46 
Day Low $4.07    EPS $0.39 
Volume 149,751